Published on 29/11/2025

Multiplex Assays and Omics: Fit-for-Purpose Validation

The increasing complexity of biologics and advanced therapy medicinal products (ATMP) necessitates comprehensive validation strategies that adhere to regulatory requirements and ensure product safety and efficacy. This tutorial discusses the validation of multiplex assays and omics approaches with a focus on viral clearance validation, particularly in the context of spiking studies, closed systems, and single-use systems.

Understanding Multiplex Assays in the Context of Validation

Multiplex assays allow for the simultaneous measurement of multiple analytes in a single sample, which is crucial in the context of characterizing biologics and ATMPs. These assays are integral in identifying potency and identity critical quality attributes (CQAs). To ensure that these assays are fit for purpose, a robust validation plan must be established, focusing on several key factors.

Planning the Validation Process

• Define Objectives: The first step in the validation process is to clearly define the objectives. This involves identifying the specific analytes to be measured and establishing how these measurements relate to the potency and identity of the product.
• Regulatory Considerations: Familiarize yourself with the relevant regulatory guidelines that govern assay validation, such as the FDA Process Validation Guidance and ICH Q5A(R2), which outlines guidelines for viral clearance studies.
• Selecting Appropriate Assays: Choose assays that are capable of meeting the necessary sensitivity, specificity, precision, and accuracy requirements. This choice should take into account factors such as reagent availability and the capabilities of your lab instrumentation.

Conducting Spiking Studies for Viral Clearance Validation

Viral clearance validation is a critical component of assuring the safety of biologics and ATMPs. Spiking studies are conducted to simulate the presence of viral contaminants and assess the capacity of the manufacturing process to eliminate these viruses. An effective plan for spiking studies should consider the following:

• Viral Selection: Determine the viruses that represent the greatest risk to product safety. This may include both enveloped and non-enveloped viruses.
• Spiking Concentrations: Establish appropriate viral loads for spiking studies. This ensures that the assay can detect the maximum expected viral concentration.
• Process Conditions: Simulate realistic manufacturing conditions during spiking studies. Use the actual closed and single-use systems as they will be utilized for production.
• Sample Collection: Collect samples at various points in the process to evaluate viral reduction capabilities effectively.

Closure Systems in Aseptic Processing

Closed systems and single-use systems in biologics manufacturing are designed to minimize the risk of contamination and maintain sterility. Validation ensures these systems are fit for purpose regarding aseptic processing. The following steps outline the approach to validation in this context:

Validation of Closed Systems

• System Design Assessment: Evaluate the design and functionality of closed systems. This includes assessing the ability to maintain sterility during the entire process.
• Performance Qualification: Conduct performance qualification (PQ) studies to verify that the systems consistently operate within established parameters.
• Environmental Monitoring: Implement environmental monitoring protocols to routinely analyze the microbial purity of products processed in closed systems.

Leveraging Single-Use Technologies

Single-use systems have become increasingly popular in the manufacture of biologics due to their flexibility and reduced cleaning requirements. The validation approach for single-use systems includes:

• Material Compatibility: Assess the compatibility of single-use materials with the product to ensure no leachables or extractables interfere with product quality.
• Scalability Testing: Conduct tests to ensure that scaling from small-scale to commercial-scale manufacturing does not compromise product quality.
• Training and Compliance: Ensure all personnel are trained in the use of single-use technologies and compliant with the validation protocols established.

The Importance of Potency and Identity CQAs

Understanding potency and identity CQAs is vital for compliance with regulatory standards. These attributes are essential indicators of product effectiveness and safety, and proper validation of these CQAs is crucial for foreign and domestic market approvals. Here’s how to approach this validation:

Characterization of CQAs

• Identifying CQAs: Determine the CQAs that are intrinsic to your product’s safety, purity, and efficacy. This may require collaboration with regulatory bodies to ensure comprehensive identification.
• Analytical Methods Development: Develop and validate analytical methods to measure the identified CQAs accurately. This validation process should comply with established guidelines, ensuring reproducibility across different laboratories.

Implementation of Quality System Frameworks

Implementing a quality management system (QMS) that encompasses all aspects of product development and manufacturing is crucial in meeting regulatory requirements. Ensure that the QMS incorporates:

• Documentation Practices: Establish robust documentation practices to maintain a clear record of all validation activities conducted.
• Continuous Improvement: Foster a culture of continuous improvement where data collected during validation informs future product iterations or validation protocols.
• Regulatory Engagement: Maintain open lines of communication with regulatory agencies such as the EMA and MHRA to preemptively address potential compliance issues.

PPQ and CPV Tailoring for ATMP Validation

Process Performance Qualification (PPQ) and Continued Process Verification (CPV) are key components in the validation lifecycle of biologics and ATMPs. Tailoring these elements ensures an effective approach to maintaining product quality throughout its lifecycle.

Establishing a tailored PPQ Plan

• Defining Critical Process Parameters: Identify and define critical process parameters (CPPs) relevant to the production of your biologics. This may include temperature, pH, and agitation rates.
• Assessing Validation Criteria: Establish validation criteria to define success in the PPQ process. This should integrate data from spiking studies and CQAs to correlate process conditions with product quality.

Implementing a Dynamic CPV Strategy

The CPV strategy should involve a continuous monitoring process that tracks defined parameters throughout the product lifecycle. This ensures:

• Real-time Data Collection: Utilize advanced data collection technologies to gather real-time data on the manufacturing process.
• Analysis of Trends: Regularly analyze data to identify trends and potential deviations in the manufacturing process that could affect product quality.
• Regulatory Compliance: Ensure that the CPV plan aligns with regulatory guidelines to maintain ongoing compliance with FDA, EMA, and other governing bodies.

Conclusion: Achieving Regulatory Compliance Through Robust Validation

A comprehensive validation strategy for multiplex assays and omics is essential for ensuring that biologics and ATMPs meet rigorous safety, efficacy, and quality standards. By implementing a meticulous validation framework that incorporates viral clearance studies, closed and single-use systems, and a detailed understanding of potency and identity CQAs, pharmaceutical professionals can facilitate compliance with global regulatory expectations.

As biotech and pharmaceutical landscapes evolve, continually adapting and enhancing validation strategies will ensure sustained compliance and product viability in an increasingly competitive field.